Armando Flor

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Mark Agius, Gabriela Kłodowska-Duda, Maciej Maciejowski et al. · Multiple Sclerosis Journal · 2017 · 142 citations · Full text

Life Sciences, Immunology, Neurology +17

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Elena Schiopu, Soumya Chatterjee, Vivien Hsu et al. · Arthritis Research & Therapy · 2016 · 81 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

Bruce Cree, Jeffrey L. Bennett, Mark Sheehan et al. · Multiple Sclerosis Journal · 2015 · 71 citations · Full text

Medicine, Neurology, Neuroscience +15

Determinants of Growth during Gonadotropin-Releasing Hormone Analog Therapy for Precocious Puberty

Martina Weise, Armando Flor, Kevin M. Barnes et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 68 citations

Medicine, Endocrinology, Bone Metabolism +16

Symptoms and Association with Health Outcomes in Relapsing-Remitting Multiple Sclerosis: Results of a US Patient Survey

Angela Williams, Jeffrey Vietri, G. Isherwood et al. · Multiple Sclerosis International · 2014 · 47 citations · Full text

Nursing, Neurology, Disability Management +15